Production (Stage)
aTyr Pharma, Inc.
ATYR
$5.30
-$0.03-0.56%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -3.39% | -17.42% | |||
| Gross Profit | 3.39% | 17.42% | |||
| SG&A Expenses | 10.22% | 7.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.30% | -12.80% | |||
| Operating Income | 0.30% | 12.80% | |||
| Income Before Tax | 0.58% | 13.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.58% | 13.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | -50.00% | |||
| Net Income | 0.58% | 13.28% | |||
| EBIT | 0.30% | 12.80% | |||
| EBITDA | 0.25% | 12.91% | |||
| EPS Basic | 4.86% | 20.55% | |||
| Normalized Basic EPS | 4.95% | 20.52% | |||
| EPS Diluted | 4.86% | 20.55% | |||
| Normalized Diluted EPS | 4.95% | 20.52% | |||
| Average Basic Shares Outstanding | 4.55% | 9.13% | |||
| Average Diluted Shares Outstanding | 4.55% | 9.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||